Show simple item record

dc.contributor.authorGuerra, Borja
dc.contributor.authorMartín Rodríguez, Patricia
dc.contributor.authorDíaz Chico, Juan Carlos
dc.contributor.authorMcNaughton-Smith, Grant
dc.contributor.authorJiménez Alonso, Sandra
dc.contributor.authorHueso Falcón, Idaira
dc.contributor.authorMontero, Juan Carlos
dc.contributor.authorBlanco Lang, Raquel
dc.contributor.authorLeón Serrano, Javier 
dc.contributor.authorRodríguez González, Germán
dc.contributor.authorEstévez Braun, Ana
dc.contributor.authorPandiella, Atanasio
dc.contributor.authorDíaz Chico, Bonifacio Nicolás
dc.contributor.authorFernández Pérez, Leandro
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2016-09-21T12:21:51Z
dc.date.available2016-09-21T12:21:51Z
dc.date.issued2016
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10902/9102
dc.description.abstractHuman Chronic Myelogenous Leukemia (CML) is a hematological stem cell disorder which is associated with activation of Bcr-Abl-Stat5 oncogenic pathway. Direct Bcr-Abl inhibitors are initially successful for the treatment of CML but over time many patients develop drug resistance. In the present study, the effects of CM363, a novel naphthoquinone (NPQ) derivative, were evaluated on human CML-derived K562 cells. CM363 revealed an effective cell growth inhibition (IC50 = 0.7 ± 0.5 μM) by inducing cancer cells to undergo cell cycle arrest and apoptosis. CM363 caused a dose- and time-dependent reduction of cells in G0/G1 and G2/M phases. This cell cycle arrest was associated with increased levels of cyclin E, pChk1 and pChk2 whereas CM363 downregulated cyclin B, cyclin D3, p27, pRB, Wee1, and BUBR1. CM363 increased the double-strand DNA break marker γH2AX. CM363 caused a time-dependent increase of annexin V-positive cells, DNA fragmentation and increased number of apoptotic nuclei. CM363 triggered the mitochondrial apoptotic pathway as reflected by a release of cytochrome C from mitochondria and induction of the cleavage of caspase-3 and -9, and PARP. CM363 showed multikinase modulatory effects through an early increased JNK phosphorylation followed by inhibition of pY-Bcrl-Abl and pY-Stat5. CM363 worked synergistically with imatinib to inhibit cell viability and maintained its activity in imatinib-resistant cells. Finally, CM363 (10 mg/Kg) suppressed the growth of K562 xenograft tumors in athymic mice. In summary, CM363 is a novel multikinase modulator that offers advantages to circumvent imanitib resistance and might be therapeutically effective in Bcrl-Abl-Stat5 related malignancies.es_ES
dc.format.extent20 p.es_ES
dc.language.isoenges_ES
dc.publisherImpact Journalses_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceOncotarget. 2016 Aug 19es_ES
dc.subject.otherBcrl-Abl-Stat5es_ES
dc.subject.otherimatinib resistancees_ES
dc.subject.otherLeukemiaes_ES
dc.subject.othernaphthaquinonees_ES
dc.titleCM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.18632/oncotarget.11425
dc.type.versionpublishedVersiones_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 EspañaExcept where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España